XHKG
9606
Market cap3.96bUSD
Oct 28, Last price
106.50
1D
0.19%
1Q
-44.21%
IPO
-43.11%
Name
Duality Biotherapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
75.52%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.80b
Net income
-2.53b
CFO
195m
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Key people
Zhongyuan Zhu
Executive Chairman of the Board, Founder, Chief Executive Officer · since 2024
Haiqing Hua
Senior Vice President, Head - Drug Discovery · since 2024
Yang Qiu
Chief Scientific Officer · since 2022
Ruiyin Chu
Vice President - Translational Medicine · since 2023
Rong Shi
Vice President - Development Science · since 2022
Xin Yu
Vice President, Head - Regulatory Affairs · since 2022
Lan Zhou
Vice President - Commercial Strategy · since 2024
Wen Si
Executive Director, Director of Human Resources · since 2024
Shaoren Zhang
Vice President - Finance, Executive Director · since 2024
Wei Gu
Chief Medical Officer · since 2022
Hua Mu
Global Chief Medical Officer · since 2025
Xin Wang
Chief Business Officer · since 2025
Wing Man Tsang
Joint Company Secretary · since 2024
Jiali Yuan
Joint Company Secretary, Head - Legal and Compliance
Zhiyang Cai
Non-Executive Director · since 2024
Tao Yu
Non-Executive Director · since 2024
Shuyin Chuai
Independent Non-Executive Director · since 2024
Independent Non-Executive Director · since 2024
Independent Non-Executive Director · since 2024
Legal address
C/O Harneys Fiduciary (Cayman) Limited
P. O. Box 10240
4th Floor, Harbour Place
103 South Church Street, Grand Cayman
George Town KY1-1002
KY
P. O. Box 10240
4th Floor, Harbour Place
103 South Church Street, Grand Cayman
George Town KY1-1002
KY
Headquarters
11F, Building A, No 868 YingHua Road
Pudong New District
Shanghai
China
Shanghai, SH 201204
CN
Pudong New District
Shanghai
China
Shanghai, SH 201204
CN
Address
A幢11楼
樱花路868号
浦东新区
上海市
上海市, SH 201204
CN
樱花路868号
浦东新区
上海市
上海市, SH 201204
CN
Trading name
映恩生物
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |